XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
Joel G. Turner(The Royal Free Hospital), Daniel M. Sullivan(Moffitt Cancer Center)
Cited by 89
Related Papers
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
|Nature Medicine|2023|226
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
|Journal of Hematology & Oncology|2016|84
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo
|Journal of Cancer|2013|78